| MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma. (NCT07574047) | Swiss Cancer Institute | 2026-09-01 |
| Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial. (NCT07593482) | Swiss Cancer Institute | 2026-09-01 |
| Overcoming Resistance to Immunotherapy Combining Gemcitabine With Ivonescimab in Advanced NSCLC (NCT07158489) | Swiss Cancer Institute | 2026-09-01 |
| Magnesium Supplementation in Advanced Non-small Cell Lung Cancer (NSCLC) (NCT07149649) | Swiss Cancer Institute | 2026-08-01 |
| Terbinafine for Biochemically Recurrent Prostate Cancer (TerbinaPro) (NCT07365423) | Swiss Cancer Institute | 2026-04-24 |
| Reduced-dose Carboplatin-doublet-chemotherapy + Cemiplimab vs Cemiplimab Monotherapy in Treatment Naive Older and Frail Patients With Metastatic NSCLC With PD-L1 <50% (NCT07020065) | Swiss Cancer Institute | 2026-04-10 |
| Feasibility of Total Neoadjuvant Treatment With HYPErthermia in Patients With High-risk Extremity and Trunk Soft Tissue Sarcoma (TNT-HYPE) (NCT06835049) | Swiss Cancer Institute | 2025-10-27 |
| NEODOXy: Targeting Breast Cancer Stem Cells With Doxycycline (NCT06452394) | Swiss Cancer Institute | 2025-07-16 |
| Primary and Acquired Resistance to Targeted Treatment in BRAF V600E-mutated Metastatic Colorectal Cancer (NCT07617610) | Swiss Cancer Institute | 2025-05-25 |
| Intratumoral INT230-6 Followed by Neoadjuvant Immuno-chemotherapy in Patients With Early TNBC. INVINCIBLE-4-SAKK (NCT06358573) | Swiss Cancer Institute | 2024-10-24 |
| Darolutamide in Metastatic Castration-Resistant Prostate Cancer (mCRPC) (NCT06401980) | Swiss Cancer Institute | 2024-10-22 |
| LIBERTY: Liquid Biopsy to Diagnose and Monitor CNS Involvement in High-risk B Cell Non-Hodgkin Lymphoma (NCT06090162) | Swiss Cancer Institute | 2024-03-12 |
| Trial Comparing Systemic Therapy Alone and With Local Ablative Treatment for Stage IV NSCL Cancer Patients (NCT06114108) | Swiss Cancer Institute | 2023-12-21 |
| Intravesical Recombinant BCG Followed by Perioperative Chemo-immunotherapy for Patients With MIBC (NCT04630730) | Swiss Cancer Institute | 2022-06-24 |
| Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). (NCT04472949) | Swiss Cancer Institute | 2021-06-25 |
| Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial. (NCT04604067) | Swiss Cancer Institute | 2021-06-25 |
| Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC (NCT04629781) | Swiss Cancer Institute | 2021-05-28 |
| SAKK 17/18 (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II (NCT04480372) | Swiss Cancer Institute | 2021-03-17 |
| Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. (NCT03993678) | Swiss Cancer Institute | 2020-10-12 |
| Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC) (NCT04245514) | Swiss Cancer Institute | 2020-07-15 |
| Copanlisib in Combination With Venetoclax in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. (NCT03886649) | Swiss Cancer Institute | 2019-11-04 |
| Extended Pelvic Lymph Node Dissection vs. no Pelvic Lymph Node Dissection at Radical Prostatectomy for intermediate-and High-risk Prostate Cancer (NCT03921996) | Swiss Cancer Institute | 2019-08-27 |
| Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma (NCT03937843) | Swiss Cancer Institute | 2019-07-29 |
| Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) (NCT03762122) | Swiss Cancer Institute | 2019-07-25 |
| Ribociclib-endocrine Combination Therapy Versus Chemotherapy as 1st Line in Visceral mBC (NCT03905343) | Swiss Cancer Institute | 2019-06-25 |
| Activity Program During Aromatase Inhibitor Therapy (NCT03786198) | Swiss Cancer Institute | 2019-03-28 |
| Ibrutinib lead-in Followed by Venetoclax Plus Ibrutinib in Patients With RR CLL (NCT03708003) | Swiss Cancer Institute | 2019-03-11 |
| 1st Line Durvalumab in PS 2 NSCLC Patients (NCT03620669) | Swiss Cancer Institute | 2018-12-04 |
| TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors (NCT03387917) | Swiss Cancer Institute | 2018-11-12 |
| NAPAGE: NAb-PAclitaxel and GEmcitabine in Advanced Soft Tissue Sarcoma (NCT03524898) | Swiss Cancer Institute | 2018-10-02 |
| Alternate Day Dosing of Pomalidomide in Patients With Refractory Multiple Myeloma (NCT03520985) | Swiss Cancer Institute | 2018-10-01 |
| Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. (NCT03406650) | Swiss Cancer Institute | 2018-05-15 |
| Nivolumab in Combination With Ipilimumab in Patients With Metastatic Renal Cell Carcinoma (NCT03297593) | Swiss Cancer Institute | 2017-12-13 |
| SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy (NCT02945813) | Swiss Cancer Institute | 2017-10-24 |
| Lurbinectedin Monotherapy in Patients With Progressive Malignant Pleural Mesothelioma. (NCT03213301) | Swiss Cancer Institute | 2017-09-28 |